Liñán-Rico L, Hernández-Castro B, Doniz-Padilla L, Portillo-Salazar H, Baranda L, Cruz-Muñoz M E, González-Amaro R
Department of Immunology, UASLP, San Luis Potosí, Mexico.
Unidad Académica Multidisciplinaria Zona Huasteca, UASLP, San Luis Potosí, Mexico.
Lupus. 2015 Oct;24(11):1184-90. doi: 10.1177/0961203315584412. Epub 2015 Apr 27.
The signaling lymphocytic activation molecule SLAMF1 (CD150) is a co-stimulatory molecule that is expressed by most immune cells, including T regulatory (Treg) lymphocytes. Since different abnormalities have been reported regarding the number and function of Foxp3+ Treg cells in patients with systemic lupus erythematosus (SLE), we decided to analyze the expression and function of CD150 in these regulatory lymphocytes in this condition. We isolated peripheral blood mononuclear cells from 20 patients with SLE, and 20 healthy controls. The expression of SLAMF1 was determined by multi-parametric flow cytometry and the suppressive function of CD4+CD25+ lymphocytes, upon engagement or not of CD150 with an agonistic monoclonal antibody, was analyzed by an assay of inhibition of cell proliferation. We observed a significantly increased expression of SLAMF1 by CD3+CD4+ helper T cells and CD19+ B cells in patients with SLE and active disease. However, similar levels of SLAMF1 expression were detected in Foxp3+ Treg cells from patients and controls. In contrast, a higher proportion of SLE patients increased their suppressive function of Treg cells upon CD150 engagement compared to healthy controls. Our data suggest that SLAMF1 is another significant piece in the intricate defective immune-regulatory function of patients with SLE.
信号淋巴细胞激活分子SLAMF1（CD150）是一种共刺激分子，大多数免疫细胞包括调节性T（Treg）淋巴细胞均可表达。由于系统性红斑狼疮（SLE）患者中Foxp3 + Treg细胞的数量和功能存在不同异常报道，我们决定分析在这种情况下这些调节性淋巴细胞中CD150的表达和功能。我们从20例SLE患者和20例健康对照中分离外周血单个核细胞。通过多参数流式细胞术测定SLAMF1的表达，并通过细胞增殖抑制试验分析CD4 + CD25 +淋巴细胞在CD150与激动性单克隆抗体结合或未结合时的抑制功能。我们观察到SLE患者和活动性疾病患者中CD3 + CD4 +辅助性T细胞和CD19 + B细胞的SLAMF1表达显著增加。然而，在患者和对照的Foxp3 + Treg细胞中检测到相似水平的SLAMF1表达。相反，与健康对照相比，更高比例的SLE患者在CD150结合后Treg细胞的抑制功能增强。我们的数据表明，SLAMF1是SLE患者复杂的免疫调节功能缺陷中的另一个重要因素。
